EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China

Kaijie Yao, Yun Bao, Ying Chen, Yan Zhong, Mengxia Yan, Wen Li, Bin Wu

Pharmacoeconomics and Policy · 2026-03 · 2 (1) · 46-53

DOI: 10.1016/j.pharp.2026.03.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacoeconomics and Policy, 2026-03. Verfasst von Kaijie Yao und 6 weiteren Autor:innen. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Yao, K., Bao, Y., Chen, Y., Zhong, Y., Yan, M., Li, W., & Wu, B. (2026). Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China. Pharmacoeconomics and Policy, 2(1), 46-53. https://doi.org/10.1016/j.pharp.2026.03.006

Vancouver

Yao K, Bao Y, Chen Y, Zhong Y, Yan M, Li W, et al. Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China. Pharmacoeconomics and Policy. 2026;2(1):46-53. doi:10.1016/j.pharp.2026.03.006

BibTeX
@article{Yao2026,
  author = {Yao, Kaijie and Bao, Yun and Chen, Ying and Zhong, Yan and Yan, Mengxia and Li, Wen and Wu, Bin},
  title = {Cost-effectiveness analysis of bevifibatide for patients with acute coronary syndrome undergoing percutaneous coronary intervention in China},
  journal = {Pharmacoeconomics and Policy},
  year = {2026},
  volume = {2},
  number = {1},
  pages = {46--53},
  doi = {10.1016/j.pharp.2026.03.006}
}
Kostenlos starten →